Advances in cancer research最新文献

In this particular chapter, we have tried to explore the essential role of biomarkers in managing different cancers, focusing on their importance in staging, prognosis, and guiding individualized treatment methodologies. We also gain significant insights into how different molecular, proteomic, and genetic cancer biomarkers can control tumor behavior, aid in predicting the outcome of patients, especially the stage of cancer, and facilitate the selection of the appropriate treatment modality. This chapter also sheds light on the most recent developments that have taken place in the field of biomarker discovery, different types of cancer biomarkers, the challenges that lie ahead in translating the research on biomarkers to a new treatment modality, and the future role of biomarkers in precision oncology.

Nanotechnology has emerged as a promising frontier in the identification and treatment of skin cancer by offering innovative platforms for targeted drug administration, real-time imaging, and enhanced therapeutic efficacy. Though preclinical results are promising and scientific enthusiasm is rising, the shift of nanotechnological breakthroughs from research laboratories to clinical environments remains hampered. The main translational problems preventing the clinical acceptance of nanomedicine in skin cancer treatment are investigated in this chapter. It explores obstacles like manufacturing scalability, reproducibility, regulatory uncertainty, clinical trial design restrictions, financial limits, and intellectual property complexity. Moreover, the chapter describes strategic ways to get beyond these obstacles: multidisciplinary cooperation, regulatory harmonization, and the inclusion of digital technologies into development pipelines together with artificial intelligence (AI). This chapter seeks to give a complete knowledge of what it takes to propel nanotechnology beyond the bench and into pragmatic, patient-centred applications in oncology by closely analysing both the challenges and possible solutions.

One of the most common cancers in the world is still skin cancer, which includes both melanoma and non-melanoma forms like squamous cell carcinoma and basal cell carcinoma. Non-specificity, drug resistance, recurrence, and patient response variability are some of the drawbacks of traditional treatment modalities. In order to overcome these obstacles and improve the treatment of skin cancer, this review investigates the combination of personalized nanomedicine and patient-centric care models. Patient-centric approaches place a high value on shared decision-making, customized treatment plans, and ongoing feedback via mobile health technologies and patient-reported outcome measures (PROMs). At the same time, personalized nanomedicine uses sophisticated nanocarriers like liposomes, dendrimers, and gold nanoparticles to deliver targeted, effective, and less toxic therapies by utilizing molecular profiling and biomarker-guided strategies. When these paradigms are applied in concert, precise drug delivery is made possible, therapeutic results are improved, and treatments are tailored to the biological and psychosocial characteristics of the patients. The potential for these integrative approaches to revolutionize standard care in dermatologic oncology is highlighted in this paper along with their recent developments, clinical uses, and potential future directions.

The world's most prevalent malignancy, skin cancer, is a major public health problem due to its high mortality, morbidity, and rising incidence. There are still limitations, such as off-target toxicity, risk of recurrence, and resistance to therapy, particularly in advanced disease, even with the progress in early detection and conventional therapies such as surgery, radiation, and chemotherapy. Employing the immune system of the body to generate targeted anti-tumor responses, immunotherapy is a game-changing strategy. Its broader success is, however, limited by clinical challenges, including immune evasion, low response rates, and adverse immune-related side effects. The application of nanotechnology to immunotherapy and theranostics is discussed in this chapter and presents a synergistic approach to refining the precision, efficacy, and individualization of skin cancer therapy. Real-time image-guided therapy, better local concentration, reduced systemic toxicity, and enhanced immunotherapeutic delivery are all facilitated through nanomaterials, ranging from liposomes and polymeric nanoparticles to metallic and carbon-based platforms. Molecular pathophysiology of the two most common types of skin cancer, melanoma and non-melanoma and most current immunotherapeutic strategies, clinical outcomes, and associated toxicities are discussed in this chapter. The applications of nanotechnology in theranostics for concurrent therapy and diagnosis, targeted delivery of checkpoint inhibitors, cancer vaccines, and adoptive cell therapy are highlighted with specific emphasis. Combinatorial nanoplatforms and bionanomaterials that can be programmed have the possibility to bypass tumor resistance and offer truly personalized treatment. The chapter concludes with consideration of the present clinical applications, challenges, and possible future directions of theranostics and nanotechnology-enabled immunotherapy for skin cancer.

Skin is the largest organ of the body, which comprises of 16 % of the body weight. It has layered structure which consists of epidermis and dermis and plays a crucial role in protection. Due to factors like UV exposure, there is rising global incidence and mortality of skin cancer and thus there is requirement for advanced treatment methods beyond current methods. So, leading to the exploration of nanotechnology-driven therapies that provide improved diagnostic capabilities, targeted drug delivery and minimized adverse effects. Photodynamic therapy (PDT) uses photosensitizers that is activated by specific light wavelengths and offers minimal invasive treatment with the help of production of reactive oxygen species that destroy cancer cells. The challenges faced by conventional PDT is overcome by advancements such as targeted delivery systems, nanocarriers and oxygen-enhancing strategies. Photothermal therapy (PTT) is also a minimally invasive cancer treatment that uses absorbing agents like nanoparticles which absorb near-infrared (NIR) light. It destroys the cancer cells whiles sparing the healthy tissue by generation of localized heat. Nanotechnology significantly enhances both photodynamic therapy (PDT) and photothermal therapy (PTT) by controlled drug release, precise tumour targeting and improved heat agent or photosensitizer stability. With the use of advanced nanocarriers and NIR-responsive systems greater efficacy in hypoxic environments, reduced side effects and deeper tissue penetration is achieved when compared to conventional approaches. While clinical translation faces challenges like scalability, standardization and safety ongoing advancements in theranostics, AI and biodegradable nanomaterials has the potential to enhance therapeutic outcomes by overcoming these drawbacks.

In oncology, biomarkers have various probable applications. They are crucial in cancer detection and are vital in diagnosis, predicting outcomes, and determining the prognosis of various types of cancer. Biomarkers are critical in enhancing treatment outcomes and reducing healthcare costs. Numerous biomolecules can be used as diagnostic, predictive, and prognostic cancer biomarkers. These biomolecules include genetic, epigenetic, transcriptomic, metabolomic, proteomic, cellular, physiological, or imaging-based biomarkers. Cancer cells or surrounding non-cancerous cells produce cancer biomarkers in response to the presence of tumors. It offers a critical insight into molecular and cellular changes associated with malignancy. Once a biomarker is identified, it helps elucidate the molecular pathways linked to the onset and progression of cancer and is used to formulate treatment. Many cancer biomarkers are already in therapeutic practice. One major challenge is the development of early-stage detection and prognostic biomarkers, as most early-stage cancers are often asymptomatic and therefore difficult to detect. This chapter will cover the broad spectrum of the role of cancer biomarkers and their application in the context of cancer detection, diagnosis, and treatment.

One of the most difficult global health issues is cancer, whose incidence and mortality rates are expected to rise significantly over the next several decades. This increasing burden highlights the need for early diagnosis, accurate prognostic tools, and predictive markers for individualized treatment plans. Biomarkers, which are measurable indicators of disease states or therapeutic responses, have become essential to modern oncology and are driving the precision medicine revolution by improving patient stratification, directing therapy choices, and facilitating disease monitoring. This review explores the development of cancer biomarkers, tracing their progression from early histopathological and serum markers to advanced molecular and immunological tools. The key biomarker categories discussed include genomic alterations such as somatic mutations, gene fusions, and copy number variations, all of which offer actionable insights for targeted therapies. Epigenetic markers, which include noncoding RNAs, histone modifications, and DNA methylation, are notable for their regulatory functions and hold promise as noninvasive diagnostic instruments. Proteomic and metabolomic methods offer useful insights into tumor biology, while circulating biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, allow real-time, noninvasive monitoring of disease progression and minimal residual disease. Immunological biomarkers such as the tumor mutational burden (TMB) and programmed cell death ligand-1 (PD-L1) expression are becoming increasingly important in guiding immunotherapy choices. This study also highlights how emerging technologies, including next-generation sequencing, liquid biopsy platforms, and artificial intelligence-based analytics, have accelerated biomarker discovery and integration into clinical workflows. The observable advantages of biomarker-driven care are demonstrated by case studies and real-world applications in a variety of cancer types. Despite tremendous advancements, obstacles such as tumor heterogeneity, intertest variability, high costs, inconsistent regulations, and differences in healthcare infrastructure prevent widespread adoption, particularly in low- and middle-income nations where access to biomarker technologies is still unequal and could exacerbate global disparities in cancer outcomes. Future directions include the use of multiplex biomarker panels, the integration of digital pathology, and the exploration of novel biomarker domains such as the tumor microenvironment and microbiome. Personalized neoantigen-based vaccines and immunotherapies also represent promising frontiers. Overall, this review underscores the transformative potential of biomarkers in reshaping cancer diagnostics and therapeutics and calls for sustained collaborative research, technological advancements, and equitable policy frameworks to realize their full global impact.

The introduction of molecular diagnostics has completely changed oncology, moving the classification based on histology to biomarker-driven precision medicine. Through the use of biomarkers genomic, transcriptomic, proteomic, metabolomic, and epigenetic changes the cancer field is able to gain much needed insights for detection at an early stage, prognosis that is accurate, and treatment selection that is personalized. The current paper looks at the high-tech molecular processes that make the discovery and use of biomarkers possible, including next-generation sequencing, mass spectrometry, and PCR-based techniques, which are capable of very sensitive detection of everything from single-nucleotide variants to complete proteomic profiles. The talk points out the successful clinical translations like EGFR inhibitors in lung cancer and PARP inhibitors in BRCA-mutant cancers, at the same time acknowledging the biggest hurdles in biomarker validation such as standardization, ethical issues, and making sure no one is left out in access to the benefits. Some of the most promising new technologies like single-cell sequencing, CRISPR-based diagnostics, and artificial intelligence are expected to bring about further revolution in the area by unraveling the complexities of tumor heterogeneity, facilitating super-sensitive detection, and assimilating data from multiple omics. The future of cancer biomarker analysis is in the application of diverse molecular layers to evolve dynamic and comprehensive profiles of individual tumors. This will enable real-time monitoring through liquid biopsy and point-of-care devices. Ultimately, the constant improvement and the interdisciplinary partnership in biomarker science are of utmost importance to the full realization of the personalized oncology's promise and the enhancement of the survival rate of all cancer patients.

Cancer remains a major health concern worldwide owing to deceased millions of individuals annually. Therefore, early detection and precise diagnosis of this deadly threat is primarily concern of the scientific community to reduce the treatment complications and improve the survival rate of individual. In this context, molecular biomarkers found in body fluids such as blood, urine, saliva, tears and cerebrospinal fluid have become important tools for predicting, diagnosing, and monitoring different cancers. These biomarkers include DNA, RNA, protein, exosomes and metabolites etc., provide valuable information about tumour development and progression. Additionally, continuous progress and advancement in molecular biology and analytical sciences playing a pivotal role in identification, real time monitoring and validation of these biomarkers with greater accuracy, sensitivity and less invasiveness approach. Techniques such as next-generation sequencing, quantitative PCR, proteomics, and liquid biopsy are increasingly being used to detect circulating tumour DNA, microRNAs, and other disease-related molecules. Even though, after these encouraging advances, few limitations still persist such as variation in biomarker levels among individuals, limited standardization of analytical methods, and the need for large-scale clinical validation. This book chapter concise the overview of predictive, prognostic, and diagnostic biomarkers in body fluids, highlighting their biological origins, numerous detection technologies, as well as their clinical significance across major cancer types. Additionally, it also includes the recent progress in integrating nanotechnology, bioinformatics, and artificial intelligence to strengthen cancer diagnostics. Besides to the above discussed major points, this chapter concludes by emphasizing the future potential of multi-omics integration and body fluid-based diagnostics in advancing precision oncology and improving patient outcomes.

Skin cancer carries a significant global health concern; the incidence is further rising due to environmental exposure and genetic predisposition. In this chapter, nanotechnology is explored in the context of its practical and clinical importance for skin cancer diagnosis, treatment, and prevention. It discusses, through real-world applications and case-based insights, how nanotechnology played a role in precise drug delivery, improved immunohistochemistry (i.e., for diagnosis and marking cells), and the manufacture of diagnostic tools for early detection. The manuscript emphasizes the use of nano enabled strategies like nanovaccines that modulate the immune system against tumor antigens, nano biosensors/ biomarker detectors, nano photothermal and photodynamic therapies. Furthermore, preventive nano-devices for high-risk people are presented in terms of wearable nano-devices that monitor ultraviolet exposure. Current literature and clinical outcomes allow this to be supported for each application, showcasing the integration of advanced materials science with oncology and how this benefits patient care. The chapter bridges theoretical innovation to clinical utility in dermatologic oncology through the example of these translational advances.